Avraham Raz
Office Address
Karmanos Cancer Institute
Position Title
Professor of Pathology, Radiation Oncology and OncologyEducation Training
Ph.D. (with distinction) The Weizmann Institute of Science, Department of Membrane
Research. Rehovot, Israel. Thesis; “Structural and Functional Changes in Cells and
Membranes in Response to Drugs and Concanavalin A” 1978
M. Sc. (with distinction) in Physiology, Ben-Gurion University of the Negev, and
the Hebrew University of Jerusalem, Israel 1972
B.Sc. (with distinction) in Biology, Ben-Gurion University of the Negev, Beer-Sheva, Israel 1970
POST GRADUATE TRAINING:
Research Fellow, the Department of Cell Biology. The Weizmann Institute of
Science, Rehovot, Israel 1980-1981
Postdoctoral Fellowship at the National Cancer Institutes, Bethesda, MD 1978-1981
Medical Education Responsibilities
SOM Faculty’s representative at WSU Faculty Senate
WSU Faculty Senate Research Committee
Professor, Department of Oncology, Wayne State University School of Medicine,
Detroit, Michigan 2012-
Professor, Department of Pathology, Wayne State University, School of Medicine
Detroit, Michigan 1992-
Director, Division of Basic Research, Comprehensive Cancer Center; Barbara Ann
Karmanos Cancer Institute, Detroit, Michigan 1995-2000 Faculty, Graduate Program in Cancer Biology, Wayne State University School of Medicine
Detroit, Michigan 1989-
Member, Cancer Comprehensive Center of Detroit, Detroit, Michigan 1988-
Adjunct Professor, Department of Radiation Oncology, Wayne State University 1988-1995
Member and Director of Cancer Metastasis Research Michigan Cancer Foundation,
Detroit, Michigan 1987-1995
Associate Professor, Department of Cell Biology; the Weizmann Institute of
Science, Rehovot, Israel 1986-1988
Senior Scientist, the Department of Cell Biology; the Weizmann Institute of
Science, Rehovot, Israel 1981-1986
Areas of Interest
Cancer, metastasis, motility, and carbohydrate-recognition
Research Interests
Cancer, metastases, motility and carbohydrate recognition
Current Lab Personnel
Professor, Professor, Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan 2012-
Professor, Department of Pathology, Wayne State University, School of Medicine, Detroit, Michigan 1992-
Publications
1. Eliaz I and Raz A (2019) Pleiotropic Effects of Modified Citrus Pectin. Nutrients (submitted)
2. Kho DH, Uddin MH, Chatterjee M, Vogt A, Raz A, Wu GS (2019) The ubiquitin specific protease USP34 protects the ubiquitin ligase gp78 from proteasomal degradation. Mol Cell Biol.39(11). pii: e00485-18. doi: 10.1128/MCB.00485-18.
3. Wang H, Ju D, Kho DH, Yang H, Li L, Raz A, Sun F, Xie Y (2019) The ubiquitin specific protease USP34 protects the ubiquitin ligase gp78 from proteasomal degradation. Biochem Biophys Res Commun. ;509(2):348-353.
4. Bernardino S, do Prado R, Shiga TM,Harazono Y, Hogan V, Raz A, Carpita CC, Fabi JP. (2019) Migration and proliferation of cancer cells in culture are differentially affected by molecular size of modified citrus pectin. Carbohydrate Polymer (In Press)
5. Dhong H-K,Uddin H,Chatterjee M, Vogt A, Raz A , Wu GS. (2019) GP78 cooperates with DUSP1 to stimulate EGFR-mediated ERK signaling Mol. Cell. Biol. (under revision)
6. Wang H, Ju D, Kho D-H; Yang H, Li L, Raz A, Sun F, Xie Y. (2019) The ubiquitin specific protease USP34 protects the ubiquitin ligase gp78 from proteasomal degradatrion. Biochemical and Biophysical Research Communications (In Press)
7. Nakajima K, Nangia-Makker P, Hogan V, Raz A. (2017) Cancer Self-Defense: An Immune Stealth. Cancer Res. 2017 Oct 15;77(20):5441-5444. doi: 10.1158/0008-5472
8. do Prado RSB, Fernandez Ferreira G, Harazono Y, Shiga TM, Raz A , Fabi JP. (2017) Ripening-induced chemical modifications of papaya pectin inhibit cancer cell proliferation. Scientific Reports 7: 16564 | DOI:10.1038/s41598-017-16709-3.
9. Nakajima K, Heilbrun LK, Smith D, Hogan V, Raz A, Heath E The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II. Oncotarget. (2017) Mar 14;8(11):17643-17650. doi: 10.186322013 .2266-82272.
10. Nakajima K, Heilbrun LK, Hogan V, Smith D, Heath E, Raz A. (2016) Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. Oncotarget.. doi: 10.18632/oncotarget.12619. PMID; 27741512
11. Nakajima K, Heilbrun LK, Hogan V, Smith D, Heath E, Raz A. (2016) Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. Oncotarget.. doi: 10.18632/oncotarget.12619. PMID; 27741512
12. Nakajima K, Heilbrun LK, Smith D, Hogan V, Raz A, Heath E. (2016) The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II. Oncotarget. 2016 Oct 12. doi: 10.18632/oncotarget.12620.PMID: 2774
13. Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, Ali-Fehmi R, Mehra R, Raz A. (2016) Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis. Cancer Res. 6(6):1391-402. doi: 10.1158/0008-5472.CAN-14-1793 PMID: 6837763
15. Menachem A, Bodner O, Pastor J, Raz A, Kloog Y (2015) Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors. Cell Death Discov.1:15047. doi: 10.1038/cddiscovery. 2015.47 PMID: 27551476
16. Harazono Y, Kho DH, Balan V, Nakajima K, Hogan V, Raz A. (2015) Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling. Oncotarget. Aug 14;6(23):19592-604.PMID:26158764
17. Wolfenden M, Cousin J, Nangia-Makker P, Raz A, Cloninger M (2015) Glycodendrimers and Modified ELISAs: Tools to Elucidate Multivalent Interactions of Galectins 1 and 3. Molecules. 20(4):7059-96. doi: 10.3390/molecules20047059. PMID:25903363
18. Zhang T, Kho DH, Wang Y, Harazono Y, Nakajima K, Xie Y, Raz A. (2015) Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer. PLoS One. 2015 Mar 19;10(3):e0118448. doi: 10.1371/journal.pone.0118448. eCollection. PMID: 25789613
19. Harazono Y, Kho DH, Balan V, Nakajima K, Zhang T, Hogan V, Raz A. (2015) Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. Oncotarget; 5(20):9992-10001. PMID: 25393982
20. Menachem A, Bodner O, Pastor J, Raz A, Kloog Y. (2015) Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors Cell Death Discovery (NPG, In Press)
21. Xu, J., Zhou, JY, Xu Z, Kho DH, Zhuang Z, Raz A, Wu GS. (2014) The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling. Cell Cycle.13:3750-8. PMID: 25551360
22. Goodman CK, Wolfenden ML, Nangia-Makker P, Michel AK, Raz A, Cloninger MJ.(2014) Multivalent scaffolds induce galectin-3 aggregation into nanoparticles. Beilstein J Org Chem. 10:1570-7. PMID: 25161713
23. Michel AK, Nangia-Makker P, Raz A, Cloninger MJ. (2014) Lactose-functionalized dendrimers arbitrate the interaction of galectin-3/MUC1 mediated cancer cellular aggregation. Chembiochem.15:2106-12. PMID:25138772
24. Gao X, Balan V, Tai G, Raz A. (2014) Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway. Oncotarget. Apr 30; 5(8):2077-84. PMID: 24809457.
25. Harazono Y, Kho D-H, Balan V, Nakajima K, Zhang T, Hogan V, Raz A. (2014) Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells Oncotarget. Oct 30; 5:9992-10001.
26. Nakajima K, Kho D-H, Yanagawa T, Harazono Y, Gao X, Hogan V, Raz A. (2014) Galectin-3 inhibits osteoblast differentiation via Notch signaling, Neoplasm Nov 20;16(11):939-49.
27. Wang Y, Ha S-W, Zhang T, Kho, D-Y, Raz, A., Xie, Y. (2014) Polyubiquitylation of AMF requires cooperation between the gp78 and TRIM25 ubiquitin ligases. Oncotarget. 5(8):2044-51. PMID:24810856
28. Kho, D, Zhang, T, Balan V, Wang Y, Ha S-W, Xie Y, Raz A. (2014) Autocrine Motility Factor modulates EGF-invasion signaling. Cancer Res 74:2229-37. doi: 10.1158/0008-5472.CAN-13-2937. PMID:24576828
29. Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L, Raz A. The significance of galectin-3 as a new basal cell marker in prostate cancer Cell Death Dis. (2013): 10.1038/cddis.2013.277. PMID: 23907467
30. Funasaka T, Balan V, Raz A, Wong R. (2013) Nucleoporin Nup98 mediates galectin-3 nuclear-cytoplasmic trafficking. Biochem. Biophys. Res Commun. 434:155-61 PMID:23541576
31. Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, Heilbrun L, Raz A, Heath E. (2013) Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 4:542-9. PMID:23625538
32. Nangia-Makker P, Raz T, Tait L, Shekhar MP, Li H, Balan V, Makker H, Fridman R, Maddipati K, Raz A. (2013) Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases Cancer Biol Ther. 14:5
33. Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L, Raz A. The significance of galectin-3 as a new basal cell marker in prostate cancer Cell Death Dis. 2013 : 10.1038/cddis.2013.277. PMID: 23907467
34. Kho, D, Zhang, T., Balan, V., Wang, Y., Ha, S-W., Xie, Y. and Raz, A. (2013) Secretion of Autocrine Motlity Factor (AMF) modulates EGF-induced invasion of breast cancer cells, (submitted
35. Wang, Ying, Kho, D., Raz, A.* and Xie, Y*. (2013) Ubiquitylation of autocrine motility factor is regulated by the ubiquitin ligase gp78/AMFR and the deubiquitinase USP34, (submitted *co-Corresponding Authors)
36. Funasaka, T., Balan, V., Raz, A., and Wong, R. (2013) Nucleoporin Nup98 mediates galectin-3 nuclear-cytoplasmic trafficking. Biochem Biophys Res Commun. 434:155-61 PMID:23541576
37. Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, Heilbrun L, Raz A, Heath E. (2013) Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 4:542-9. PMID:23625538
38. Nangia-Makker P, Raz T, Tait L, Shekhar MP, Li H, Balan V, Makker H, Fridman R, Maddipati K, Raz A. (2013) Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases Cancer Biol Ther. 14:5 PMID:23380593
39. Kho, D., Nangia-Makker, P., Balan, V., Hogan, V., Tait, L., Wang, Y. and Raz, A. (2012) Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells. Cancer Cancer 73:1411-9 PMID: 23248119
40. Ahmad. A., Ali. S. ,Ahmed, A., Ali. A,. Raz, A., Sakr, W., and Rahman, KM. (2013) 3, 3'-diindolylmethane enhances the effectiveness of Herceptin against HER2/neu-expressing breast cancer cells. PLoS ONE 8:54657 PMID:23372748
41. Nangia-Makker, P., Balan, V. and Raz, A. (2013) Galectin-3 binding and metastasis. . Methods Mol Biol. 878:251-66. PMID:22674139
42. Wang, Y., Kho, D., Hogan, V., Nangia-Makker, P., and Raz, A. (2012) Galectin-3 regulates p21 stability in human prostate cancer cells. Oncogene 10.1038. PMID:23160381
43. Braeuer RR, Zigler M, Kamiya T, Dobroff AS, Huang L, Choi W, McConkey DJ, Shoshan E, Mobley AK, Song R, Raz A, Bar-Eli M. (2012) Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin. Cancer Res.. Epub 2012 PMID:22986745
44. Yanagawa, T., Shinozaki, T., Watanabe, H., Saito, K., Raz, A., and Takagishi, K. (2012) Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas. Exp. Cell Res 318(7);800-808. PMID 22326461
45. Balan V, Nangia-Makker P, Kho D, Wang Y, Raz A (2012) Tyrosine phosphorylated galectin-3 is resistant to PSA cleavage. . J Biol Chem. 2012 Jan 9. [Epub ahead of print] PMID: 22232548
Other Information
MAJOR PROFESSIONAL SOCIETIES:
American Association for Cancer Research
American Society for Cell Biology
American Association for the Advancement of Science
European Association for Cancer Research
Metastasis Research Society
Southwest Oncology Group
HONORS/AWARDS:
PLoS One-Top 25% cited publication 2016
Neoplasia- Top cited paper 2016
Nominator for the Dan David Prize (Israel) 2014-
“Faculty Award for Career Achievement”, Karmanos Cancer Institute, Detroit, MI 2013
“Kales Award in Oncology”, Karmanos Cancer Institute, Detroit, MI 2013
“Outstanding Research Achievement Award”, Wayne State University, SOM, Detroit, MI 2013
Organizing Committee and Plenary Lecture, Tumor Microenvironment – Suzhou, China 2012
Chair- The 8th Annual Midwest Carbohydrate Research Symposium, WSU, Detroit, MI 2012
Reuben Lotan Distinguished Lecture- University of Texas, MD Anderson Cancer Center 2011
“MERIT Award”, Division of Cancer Biology, National Institute of Health, National Cancer
Institute,-The Role of Tumor Cell Surface Lectins in Metastasis, R37CA046120-19 2007
“Featured Synopsis in Profiles and Legacies”, Cancer Biology and Therapies,
Sugar Recognition and Metastasis, From the Birth of a Research Field to the Clinic, 2006
“Paget-Ewing” Award – International Metastasis Research Society 2004
UTMD Anderson Cancer Center President International Metastasis Research Society 2002
President, International Metastasis Research Society 1998-2000
Charter Member-The International Cancer Microenvironment Forum, Israel 1996
Invited member of the Michigan State Legislative Committee 1995
International Journal of Oncology – Featured Cover Story 1994
The Maximilian-Nitze Award - The German Urological Society 1992
Board of Directors - The International Metastasis Society 1992
Endowed Chair-The Paul Zuckerman Support Foundation for Cancer Research.
Michigan Cancer Foundation 1987
Leo & Julia Forsheimer. Center for Molecular Genetics. The Weizmann Institute of
Science 1987
"H. Dudley Wright Research Award" in Membrane Research. The Weizmann Institute
of Science 1985
Incumbent of the Sophie M.T. & Richard S. Richards Career Development Chair in
Cancer Research in perpetuity. Endowed by Mrs. Sophie M.T. Richards 1983
"Bondi Memorial Award" for graduate students of the Feinberg Graduate School of the
Weizmann Institute of Science 1978
SERVICE:
Wayne State University
Wayne State University Research Committee, Detroit, MI 2017-
Space Committee, Karmanos Cancer Institute, Detroit, MI 2010-
Faculty Development and Mentoring Program, Karmanos Cancer Institute, Detroit MI 2010-
Department of Immunology Space Committee, Karmanos Cancer Institute, Detroit, MI 2010
Scientific Leadership Council Member, Karmanos Cancer Institute, Detroit, MI 2004
Academic Search Committee, Karmanos Cancer Institute, Detroit, MI 2000
Cancer Center Support Grant Operating Committee, Karmanos Cancer Institute, Detroit, MI 2000
Patent Committee, Karmanos Cancer Institute, Detroit, MI. 1996
Outstanding Research Outstanding Faculty Mentoring Award Committee,
Wayne State University, School of Medicine, Detroit, MI 2016
Outstanding Faculty Mentoring Award Committee, Wayne State University, School of
Medicine, Detroit, MI 2016
Chair, Pathology, Mentoring Committee, Wayne State University, School of Medicine,
Detroit, MI 2016
Wayne State University Research Committee 2016
Promotion and Tenure Committee, Department of Oncology, Wayne State University Chair 2014
The 8th Annual Midwest Carbohydrate Research Symposium, Wayne State University 2012
Wayne State University Sabbatical Committee 2012
Scientific Leadership Council Member, Karmanos Cancer Institute 2004
Academic Search Committee, Karmanos Cancer Institute, Detroit, MI 2000
Cancer Center Support Grant Operating Committee, Detroit, MI 2000
Joint WSU-AAUP Panel 1999
Patent Committee, Karmanos Cancer Institute, Detroit, MI 1996
Chair, Pathology Research Committee, Wayne State University, School of Medicine,
Detroit, MI 1994
Chair, Mentoring Committee, Wayne State University, School of Medicine, Detroit, MI 1994
Professional:
Japan Broncho-Esophagological Society 2007
American Chemical Society 2005
South American Immunological Society, Buenos Aires 2004
Japan’s Urological Society 2002-2003
World Congress on Advances in Oncology 1999
International Bladder Research Congress 1998
World Congress on Biomedical Sciences 1996
Keystone Symposia 1995
FASEB Summer Research Conference 1990
Lake Ontario Metastases Group 1988
Gordon Research Conference 1988-1991
Metastasis Research Society 1988-
Consulting:
Charter Member: The International Cancer Microenvironment Forum, Israel 1996
Nominator of the General Motors Cancer Research Foundation, New York, NY 1996
Scientific Advisory Board, Hipple Cancer Research Center, Dayton OH 1995
Consultant Expertise, National Institute of Cancer, Bethesda, MD 1989
Scholarly Service:
Grant Review Committees:
National:
Plenary Speaker; Inaugural Symposium on Cancer Metastasis in Honor Of Isaiah J. Fidler * Celebration 50 Years of Cancer Metastasis Research* March 2019
Reviewer, State of Pennsylvania for Cancer Research 2018
Reviewer, State of Florida Commission for Cancer Research 2016
Reviewer, Cancer Prevention & Research Institute of Texas, November 2014-2017
Reviewer, Melanoma Research Foundation 2013-
Reviewer, NIH/NCI Career Development Review Committee, Bethesda, MD 2013
Reviewer, PA Department of Health on Cancer Commercialization 2012
Reviewer-United States Israel Bi National Science Foundation (BSF) 2012-
Reviewer, NIH, National Cancer Institute, K1C 2011
Reviewer, Department of Oncology, Grant Review, National Cancer Institute Grants 2010
Reviewer, NIH, Division of Cancer Treatment and Diagnosis, Developmental Therapeutic
Program 2010
Reviewer, National Science Foundation 2010
Scientific Review Committee AACR Basic Cancer Research Fellowships 2009
Reviewer, NIH, Center for Scientific Review, Cell Biology Integrated Review Group, MIST 2009
Reviewer, NIH, Special Emphasis Panel, ZRG 1CB-N 02(M), Cell Biology 2009
National Center for Glycomics and Glycoproteins Advisory Board, NIH, Site Visit, IN 2009
Reviewer, DOD, BCRP, Study Section 2009
Ad hoc Committee Member, AACR Grants Sub-Committee for Basic Cancer Research 2008
Reviewer, Special Emphasis Panel/Scientific Review Group 2008/05 ZRG1 ONC-U (92) 2008
Reviewer, Discovery and Development, Special Emphasis Panel, NIH Study Section 2008
Reviewer, Cellular and Molecular Biology Special Emphasis Panel, NIH, Study Section 2008
Member, Reviewer, Center for Scientific Review, Tumor Progression and Metastasis, NIH
Study Section
Reviewer, State of Pennsylvania Commission for Cancer Research 2007
Reviewer, Special Emphasis Panel, NCI (CCNE) Centers for Cancer, Nanotechnology
Excellence 2007
Reviewer - Congressionally Directed Medical Research Program (CDMRP) 2006
Prostate Cancer Research Program Pathobiology-2 Panel, USARMRC, DOD 2006
Reviewer – Center for Scientific Review, Oncological Sciences Integrated Review Group
Tumor Progression and Metastasis, Study Section 2005
Reviewer – Center for Scientific Review, Oncological Sciences Integrated Review Group
Tumor Progression and Metastasis, Study Section 2005
Reviewer-Israel Cancer Research Fund (ICRF) 2004
Board of Directors, International Tumor Microenvironment Conference 2003
Reviewer, Special Emphasis Panel, National Institutes of Health, Nutrition and Prostate
cancer ZCA1 SRRB-D (J2) 2003
Reviewer-Ad Hoc PTHB - Study Section, National Institutes of Health 2003
Member-BCRP, Breast Cancer Research Program, USARMRC, DOD 2003
Chair- ZRG1 CPA(04) Center for Scientific Review Special Emphasis Panel on Metastasis
and Invasion, National Institutes of Health, Bethesda, MD 2003
Member-NCI-C GRB-I (T3), National Institutes of Health, Study Section 2002
Reviewer-State of South Carolina, Collaborative Research Program (CRP –EPSCOR 2002
Member-ZRG1 CPA (02) Special Emphasis Panel, Center for Scientific Review, NIH 2002
Member-BCRP, Breast Cancer Research Program, USARMRC, DOD 2002
Member- PCRP, Prostate Cancer Research Program, USAMRC, DOD 2001
Member- DDG, Drug Development Review Group, National Cancer Institute 2000
Reviewer-US Civilian Research Development Foundation (CRDF) 2000
Reviewer-USAMRMC, Prostate Cancer Research Program, Cancer Center Proposal 1999
Member-ZRB1-ET-1 05, Special Emphasis Panel, SRA Experimental Therapeutics-1 1999
NIH Ad Hoc PTHB - Study Section, NIH 1999
Member-ZCA1-SRC(99) Special Emphasis Panel, NIH, Reviewer 1999
Reviewer-Vanderbilt University Medical/Cancer Center, Pilot Project Program 1999
Member-ZRG1-MEP-02M Special Emphasis Panel, NIH, Reviewer 1998
Member-ZRG1-MEP-01M Special Emphasis Panel, NIH, Reviewer 1998
Member-ZRG2 MEP (03) Biological and Physiological Sciences Special Emphasis Panel 1998
Center for Scientific Review, National Institutes of Health, Reviewer 1998
Member-SRA, MEP Study Section, Special Emphasis Section, NIH, Site visit, Program Project 1998
Reviewer-MD Anderson Cancer Center, ISD Conference, Houston, TX 1998
S.P.O.R.E. Operating Committee, University of Michigan, Comprehensive Cancer Center 1997
Member, Biology and Physiological Sciences Special Emphasis Panel 1997
Ad Hoc Member, Experimental Immunology Study Section, NIH 1997
Member-Biological and Physiological Sciences Special Emphasis Panel NIH
Bethesda, MD 1997
Member-Oncological Sciences Special Emphasis Panel, NIH, Bethesda, MD 1997
Ad Hoc Member, Biology Subcommittee Section, Invasion and Metastasis, American
Association of Cancer Research 1996
Ad Hoc Member, Biochemical Genetics Study Section, National Science Foundation 1996
Member-Oncological Sciences Special Emphasis Panel, NIH , Bethesda, MD 1996
Nominator of the General Motors Cancer Research Foundation, New York, NY 1996
Ad Hoc Member- PTHB Study Section - NIH, Bethesda, MD 1995
Member-PTHB Study Section - NIH, Bethesda, MD 1995-1998
Outside Advisor - Biochemistry and Endocrinology Scientific Advisory Committee,
American Cancer Society 1995
Ad Hoc Member ZRG-MED B (2) L F31 Minority Pre-doctoral Fellowship, National Institutes
of Health, Bethesda, MD 1995
Ad Hoc Member RFA-CA95-006, NIH, Bethesda, MD 1995
Ad Hoc Member Cell Biology Study Section, American Cancer Society, Atlanta, GA 1995
Scientific Advisory Board, Hipple Cancer Research Center, Dayton OH 1995
Reviewer- Ohio Cancer Research Associates 1995
Reviewer-United States- Israel Bi National Science Foundation (BSF) 1994-
Reviewer- State of New Jersey, Commission on Cancer 1992
Ad Hoc Member- PTHB Study Section - National Institutes of Health, Bethesda, MD 1988-1995
International:
Consultant University of Lichtenstein 2017
Reviewer and site visit UK Cancer Research UK 2017
Reviewer Fonds National de La Recherche, Luxembourg 2017
Reviewer, Cancer Research, UK 2015
Reviewer-Israel Ministry of Science and the Arts 2012-
Reviewer, the Flemish League Against Cancer 2012
Worldwide Cancer Research Foundation, UK 2012
The British Lung Foundation 2011
Reviewer Israel-DFKZ 2011
Reviewer, Prostate Cancer Charity Research Awards;The Cancer Research, UK 2010
Reviewer – North West Cancer Research Fund Scientific Committee (NWCRF),
Project Grant, London, UK 2006
Reviewer- German-Israeli Foundation for Scientific & Research Development 2000
Reviewer-Israel Academy of Science 1994-
Reviewer-Austrian Science Foundation (FWF) 1994
Reviewer-Ministry of Science and the Arts (Israel) 1993-
Reviewer- State of New Jersey, Commission on Cancer 1992
Reviewer- Medical Research Council of Canada (MRC) 1992-
Reviewer-National Cancer Institute of Canada (NCIC) 1992-
Editorship:
Editorial Board Member – Clinics in Oncology 2017-
Editorial Board Member - Cellular and Molecular Biology 2015-
Editorial Board Member - Madridge Journal of Cancer Study & Research (MJCSR). 2015-
Editorial Board Member - Breast Cancer: Targets and Therapy 2015-
Editorial Board Member - International Journal of Cancer and Oncology 2015-
Editorial Board Member - Annals of Cancer Research 2014-
Editorial Board Member - Journal of Cancer Research & Therapy 2013-
Editorial Board Member -Journal of Oncobiomarkers 2012-
Editorial Board Member - Datasets Papers in Biology 2012-
Editorial Board Member - Journal of Cancer Research & Therapy 2012-
Editorial Board Member - Current Cancer Therapy Reviews 2009-
Editorial Board Member – Glycoscience 2007-
Editorial Board Member - Cancer Microenvironment 2007
Editorial Advisory Board Member – Current Cancer Therapy Reviews 2005-2009
Managing Editorial Board - Frontiers in Bioscience 2003
Managing Editorial Board - Frontiers in Science 2002
Chief Editor in Chief, Cancer Metastasis Reviews 2002-
Editorial Board - Cancer Biology and Therapy 2001-
Associate Editor - Cancer Research 2001-2010
Editorial Board, Invasion & Metastasis 1996-
Editorial Board, Clinical & Experimental Metastasis 1995-
International Editorial Board, Pathology & Oncology Research 1994-
Editorial Academy of the International Journal of Oncology 1993-
Editorial Advisory Board: Cancer Metastasis Reviews 1983-2002
Review of Manuscripts – since 1988 (To name a few)
AJP; Breast Cancer Treatment; CMR; Cancer Res; Clinical Cancer Research;
Clinical and Experimental Metastasis; FASEB Journal; Gastroenterology; Glycobiology;
International Journal of Cancer; JBC; JCI; JNCI; MCB; MJB; Nature;
Nature Review of Cancer; Neoplasia; Oncogene; PLoS One; PNAS;Science,.
Visiting Professor/Invited Lecturer
Organizing Committee, Plenary Lecture ‘Tumor Microenvironment’ Lisbon, Portugal 2018
Plenary speaker and Chair; EMBO workshop on Galectin, Nice, France 2016
Plenary speaker The 7th International Conference on Tumor Microenvironment:
Progression, Therapy & Prevention 2015
Invited Lecturer, University of Montana, Department of Chemistry, Bozeman MT 2015
Plenary speaker and session chair EMBO workshop on Cell Biology of Animal
Lectins-Israel 2015
Visiting Professor: Tel Aviv University, Department of Neurobiology, George S
Wise Faculty of Life Sciences, Tel Aviv, Israel 2015
Plenary speaker The 7th International Conference on Tumor Microenvironment:
Progression, Therapy & Prevention 2015
Visiting Professor: Tel Aviv University, Department of Neurobiology, George S.
Wise Faculty of Life Sciences, Tel Aviv, Israel 2015
Visiting Professor, Northeast Normal University, Changchun, China, 2013
Chair Person the 8th Annual Midwest Carbohydrate Research Symposium, WSU 2012
Invited Lecturer: Wayne State University, Department of Biology, Detroit, MI 2012
Invited Lecturer: Reuben Lotan Distinguished Lecture- University of Texas, MD
Anderson Cancer Center 2012
Grand Rounds: Wayne State University, DMC- Karmanos Cancer Institute,
Detroit, MI 2012
Keynote Speaker, 26h Annual Research Meeting of the Japanese Orthopedic
Association, Gunma, Japan 2012
Visiting Professor: Department of Orthopedic Surgery, Gunma University
Graduate School of Medicine, Gunma Japan 2012
Invited Lecturer, UTMD Anderson Cancer Center, Houston, TX 2012
Invited Lecturer, 7th Midwest Carbohydrate and Glycobiology Symposium, Michigan
State University 2012
Organizer and Plenary Lecture Cold Spring Harbor Asia / International Cancer
Microenvironment Society Joint Conference on Tumor Microenvironment 2012
Visiting Professor: Tel Aviv University, Department of Neurobiology, George S. Wise
Faculty of Life Sciences, Tel Aviv, Israel 2011
Invited Lecturer: The Role of Galectin-3, Osaka University, Osaka, Japan, 2011
Visiting Professor: Department of Otolaryngology, Osaka University School of Medicine,
Osaka, Japan 2011
Invited Lecturer: UC Davis Cancer, Basic Science Division, Sacramento, CA, 2009
Invited Lecturer: VA Research Seminar Series, John D. Dingell VA Medical Ctr.
Detroit, MI 2009
Invited Lecturer: New York University Cancer Institute, New York, NY 2008
Invited Lecturer: UTMD Anderson Cancer Center, Office of Provost, Houston, TX 2008
Invited Lecturer: Tel Aviv University, Charles Heidelberger Symposium on Cancer
Research, Tel Aviv, Israel 2008
Plenary Lecturer- Japan’s 59th Broncho-Esophagological Society, Osaka Japan 2007
Invited Lecturer: UTMD Anderson Cancer Ctr. Dr. I.J. Fidler Reunion Seminar, Houston, TX 2007
Invited Lecturer: Tel Aviv University, Dept. of Neurobiochemistry, Tel Aviv, Israel 2007
Invited Lecturer: Northwestern University, Chicago, IL 2006
Invited Lecturer: UTMD Anderson Cancer Center, Dept. Internal Medicine, Houston, TX 2006
Invited Lecturer: The Ben-Gurion University of the Negev, Beer-Shiva, Israel 2006
Invited Lecturer: UTMD Anderson Cancer Center, Dept. of Gastroenterology, Houston, TX 2005
Invited Lecturer: Grand Rounds, UTMD Anderson Cancer Center, Houston, TX 2004
Invited Lecturer: Grand Rounds, Children’s Memorial Hospital, Univ. of Chicago, Chicago, IL 2004
Invited Lecturer: Ellis Fischel Cancer Center, Columbus University, Columbus, MO 2003
Invited Lecturer: Haifa University and Tel Aviv University, Tel Aviv, Israel 2003
Invited Lecturer: Columbia University, New York, NY 2003
Invited Lecturer: Grand Rounds, University of Minnesota, Mayo Clinic, Minneapolis, MN 2002
Invited Lecturer: University of Louisiana, LSUHSC - Feist-Weiller Cancer Ctr. Fall Seminar 2002
Visiting Professor: University of Tokushima, School of Medicine, Tokushima, Japan 2002
Visiting Professor: Department of Oncology and Neurosciences, University
G. D'Annunzio Medical School, Chieti, Italy 2002
Invited Lecturer: USC Keck School of Medicine, Department of Biochemistry and
Molecular Biology, Los Angeles, CA 2001
Visiting Professor: University of Pennsylvania, Pathology and Laboratory Medicine,
Philadelphia, PA.
Plenary Lecturer- The Japanese Metastasis Society, Tokushima, Japan 2001
Plenary Lecturer- British Cancer Research Meeting, United Kingdom 2001
Invited Lecturer: Department of Biochemistry, Meharry Medical College, Nashville, TN 2000
Invited Lecturer: Department of Pathology, SUNY Health Science Center, Syracuse, NY 2000
Invited Lecturer: 3rd Michigan Prostate Research Colloquium, Michigan State University,
Lansing, MI 2000
Invited Lecturer 5Oth Annual Symposium on Fundamental Cancer Research Molecular
Determinants of Cancer Metastasis, UT MD Anderson Cancer Center, Houston, TX 1997
Invited Lecturer, the UTMD Anderson Cancer Center, Houston, TX 1997
Invited Lecturer, the University of Iowa, IA 1997
Visiting Professor 1st Institute of Pathology and Experimental Cancer Research,
Budapest, Hungary 1995
Visiting Professor, Tel Aviv University, George S. Wise Faculty of Life Sciences, The
Tumor’s Microenvironment 1995
Invited Lecturer Influence on Cancer Progression and Implications for Prevention and
Therapy, Tel Aviv, Israel 1995
Invited Lecturer Keystone Symposia on Molecular and Cellular Biology, Cancer Cell
Invasion and Motility, Tamarron, Colorado 1995
Invited Lecturer 4th International Conference, Eicosanoids and Other Bioactive Lipids in
Cancer, Inflammation and Radiation Injury, Hong Kong 1995
Invited Lecturer Fifth International Congress of the Metastasis Research Society, Tiberius,
Israel 1994
Invited Lecturer 3rd International Conference, Eicosanoids and Other Bioactive Lipids in
Cancer; Inflammation and Radiation Injury, Washington, D.C. 1993
Invited Lecturer 7th European Conference on Clinical Oncology and Cancer Nursing,
Jerusalem, Israel 1993
Invited Lecturer Universitatsklinikum Essen, International Symposium, "Immunotherapy in
Vising Professor Third Department of Internal Medicine, University of Tokushima School
of Medicine, Japan 1992
Uro-Oncology", Congress Center Messe Essen, Germany 1992
Invited Lecturer Fourth International Congress of the Metastasis Research Society,
Paris, France 1992
Invited Lecturer University of Texas M.D. Anderson Cancer Center's 35th Annual Clinical
Conference, "Advances in the Biology and Clinical Management of Melanoma",
Houston, TX 1991
Invited Lecturer Medical College of Wisconsin, "Role of Cell Migration in Tumor Invasion",
Milwaukee, WI 1991
Invited Lecturer Gordon Research Conference on Cancer, Salve Regina College,
Newport, RI 1991
Invited Lecturer 2nd International Conference on Eicosanoids and Bioactive Lipids in
Cancer, Inflammation and Radiation Injury, Klinikum Steglitz Berlin 1990
Organizing Committee Third International Conference of Anticancer Research, Greece 1990
FASEB Summer Research Conference on Molecular Aspects of Metastasis, USA 1990
Invited Lecturer International Symposium: Critical Determinants in Cancer Progression
and Metastasis. U.S.A. 1990
International Advisory Committee, Session Chairman First International Conference on
Eicosanoids and Bioactive Lipids in Cancer & Radiation Injury, U.S.A., 1989
Symposium: Frontiers in Cancer Research, U.S.A. 1989
Invited Lecturer: CIBA Foundation Symposium on Metastasis, United Kingdom 1989
Invited Lecturer Sapporo Cancer Seminar: Symposium on Cancer Progression and
Metastasis, Japan 1989
Invited Lecturer: Gordon Research Conference Meeting: Genetic Determinants of
Cancer Etiology, Development, and Phenotype. RI 1988
Invited Lecturer 2nd International Conference of the Metastasis Research Society
Together with The-SEK-of the Deutsche Krebsgesellschaft. Germany 1988
Organizing Committee; Second International Conference of Anticancer Research.
Greece 1988
Organizer: Lake Ontario Metastases Group Meeting. U.S.A. 1988
Invited Lecturer: Symposium on Tumor Progression and Metastasis. UCLA Los Angeles, CA 1988
Invited Lecturer International Congress on Cancer Metastasis: Biological and
Biochemical Mechanisms and Clinical Aspects. Italy 1987
Organizer Bat-Sheva Seminar on Tumor Malignancy: Pathogenesis and Prevention of
Tumor Dissemination. Israel 1987
Plenary Speaker: Lake Ontario Metastasis Group Meeting. Canada 1987
Session Chairman: Biological and Therapeutic Aspects of Cancer Metastasis. Spain 1987
Session Chairman: Franco-Israeli Colloquium on Lectins. France 1986
Organizer: International Workshop on Membranes in Tumor Growth. Italy 1985
Session Chairman: First International Conference of Anticancer Research. Greece 1985
Organizer Bat-Sheva Seminar on Tumor Metastasis: Control Mechanisms. Israel 1983
Invited Lecturer: International Workshop on Membranes in Tumor Growth. Italy 1982
Funding:
Active/ Pending National/International Grants and Contracts:
NATIONAL INSTITUTES OF HEALTH Gp78 ubiquitin ligase suppresses non-
alcoholic fatty liver disease and liver cancer, Xie, Youming: PI, Co-PI - 10% (pending) 2018-2023
NATIONAL INSTITUTES OF HEALTH Melanoma Antigen Radiomics of Tumors with
PhotoAcoustic Imaging (SMART-PAI) Mohammadreza Nasiriavanaki PI – Co-PI 1%
(Pending) 2018-2021
5R01GM062444-06 NIH: NCI: Using Dendrimers to Design Multivalent Therapeutic
Agents Subcontract: Montana State University, $50,000 PI: Mary Cloniger – Co-PI 5% 2012-2017
R37CA-46120-19 NIH-NCI, DHHS: The Role of Tumor Cell Surface Lectin in
Metastasis $283,000, ADC 2008-2017
WSU –Office of Vice President Grants Plus Program: Extending Research on ‘The Role of
Tumor Cell Surface Lectins in Metastasis’ Total Awarded $75,000 2013-2014
11-053-01-IRG pilot project: ACS: The interplay between prostate specific antigen and
Galectin-3 during prostate cancer progression. Amount Awarded - $30,000 2011-2012
2 RO1-CA51714 - NCI, DHHS: Characterization of Motility Factor Receptor,
$250,000, ADC 2009 2013
5R01GM062444-06 NIH:NCI: Using Dendrimers to Design Multivalent Therapeutic Agents
ADC: $50,000 Subcontract: Montana State University, PI: Mary Cloninger 2007-2016
2R01CA-69480-09A3 NIH:NCI Mucin glycoproteins in colorectal cancer metastasis ADC:
$50,000 Subcontract: MD Anderson, PI: Robert Bresalier, Co-PI-10% 2006-2011
R13-CA112671-01 NIH: NCI, DHHS. Conference grant The Third International Conference
on Tumor Microenvironment: Progression, Therapy and Prevention, $10,000. 2004-2005
2 RO1-CA51714 - NIH: NCI, DHHS, Characterization of Motility Factor Receptor,
$100,000 2002-2006
RO1-CA46120- NIH:NCI, DHHS, The Role of Tumor Cell Surface Lectin in Metastasis,
$250,000 ADC 2002-2007
17-00-1-0497 - USAMRMC - DOD, Endothelial Cell Morphogenesis and Angiogenesis
Mediated by Carbohydrate-Binding Protein Galectin-3, A. Raz, PI. $111,666 ADC 2000-2003
RO1 CA69480 Subcontract: NCI: Mucin Glycoproteins in Colon Cancer Metastasis, R.
Bresalier, Henry Ford Health Center, PI, Co-PI-10% 1999-2000
R21 CA80660 NIH/ University of Michigan, Prostate Cancer Metastasis to Bone, K.
Pienta, PI ,Co-PI 10% 1999-2001
RO1-CA51714 - NIH: NCI, DHHS, Characterization of Motility Factor Receptor, $224,168
ADC 1999-2003
RO1-CA46120 – NIH: NCI, DHHS, The Role of Tumor Cell Surface Lectin in Metastasis,
$200,588 ADC 1997-2001
RO1 CA69480 Subcontract, NCI: Mucin Glycoproteins in Colon Cancer Metastasis, R.
Bresalier, Henry Ford Health Center, Co-PI $21,959, ADC 1996-1999
Hercules, Inc: Characterization of Modified Citrus Pectin, $140,913, ADC 1996-1999
RO1 CA443083 – Subcontract; NCI/University of Michigan, SPORE in Prostate Cancer, K.
Pienta, PI, $37,311, ADC 1995-2002
RO1-CA51714 – NIH: NCI, DHHS, Characterization of Motility Factor Receptor, $106,111
ADC 1994-1999
UroCor: Detection of Autocrine Motility Factor Receptor in the Urine of Cancer Patients,
$40,749 ADC 1993-1996
RO1-CA51714 – NIH: NCI, DHHS Characterization of Motility Factor Receptor, $106,111
ADC, UroCor: Detection of Autocrine Motility Factor Receptor in the Urine of Cancer
Patients, $40,749 ADC 1993-1996
PHS RO1-CA46120- NIH: NCI, DHHS, The Role of Tumor Cell Surface Lectin in Metastasis,
$186,036 ADC 1992-1997
PHS RO1-CA51714 - Grant awarded by the National Cancer Institute, DHHS, USA,
Characterization of Motility Factor Receptor, $96,111 ADC. 1991-1994
PHS RO1-CA51714 - Grant awarded by the National Cancer Institute, DHHS,
USA, Characterization of Motility Factor Receptor, 1991-1994, $96,111 ADC. 1991-1994
CTR-2902, Council For Tobacco Research, NY, Carbohydrate-binding protein and
metastasis, $75,000, Annual Funding 1991-1994
The Minerva Foundation, Federal Republic Germany 1988-1989
The American Cancer Society (wavered), Same as PHSR01-CA51714 1988-1989
PHS RO1-CA46120- NIH:NCI, DHHS, USA The Role of Tumor Cell Surface Lectin
in Metastasis, $97,490 ADC. 1987-1991
PHS RO1-CA39422- NIH:NCI, DHHS, The Role of Tumor Cell Surface Lectin in
Metastasis, $97,490 ADC 1986-1988
Israel Cancer Research Fund, USA 1986-1988
National Council for Research and Development, Israel and DKFZ, Heidelberg, Federal
Republic of Germany 1984-1987
AMGen, Boulder, CO 1983-1986
Abic, Ltd 1982-1987
The Israel Cancer Association, Israel Cancer Research Fund, USA 1980-1982
PATENTS Awarded
US Patent No: 8,349,579 Galectin-3 cleavages as a diagnostic marker for MMP-2 and –
9 activity in cancer tissue, A. Raz, P. Nangia-Makker, R Fridman; Wayne State University
US Patent No: 6,389,312: Method for Preventing Cancer and Inhibiting Angiogenesis with
Modified Pectin, PI
US Patent No: 5,895,784: Method for treatment of Cancer by Oral Administration of Modified
Pectin, PI
US Patent No: 5,801,002: Galactoside Binding Protein Useful in the Diagnosis and Inhibition
of Metastasis, PI
US Patent No: 5,650,500: Method of Determining Metastatic Potential of Bladder Tumor Cells, PI
US Patent No: 5,541,298: Method of Determining Metastatic Potential of Tumor Cells, PI
US Patent US 8349579 B2, Galectin-3 cleavage as a marker for matrix metalloproteinase
activity in cancer.: Method of Determining Metastatic Potential of Bladder Tumor Cells PI